[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"squamous-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:squamous-cell-lung-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,75,102,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100485902","phase-2-a-study-of-zen003694-in-people-with-squamous-cell-lung-cancer-100485902",false,"NCT05607108","A Study of ZEN003694 in People With Squamous Cell Lung Cancer","Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification","Inclusion Criteria:\n\n* Histologically-confirmed squamous cell lung cancer\n* Recurrent or metastatic disease\n* Patients with previously treated asymptomatic brain metastases requiring no more than 10mg prednisone (or equivalent) are allowed. Patients with asymptomatic brain metastases ≤ 1cm not requiring more than 10mg prednisone (or equivalent) are allowed.\n* Received prior first-line therapy: platinum-based chemotherapy and immunotherapy, given either concurrently or sequentially\n* Eastern Cooperative Oncology Group (ECOG) PS 0-2\n* Evidence of NSD3 gain or amplification by NGS, including but not limited to evidence of 8p11 gain or amplification as determined by MSK IMPACT or MSK ACCESS, or a commercially available molecular assay that is FDA authorized. Note: ctDNA testing, including but not limited to MSK ACCESS and Guardant and Foundation\n* Adequate laboratory parameters at Screening including:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL\n  * Platelet count ≥ 100,000\u002Fmm\\^3\n  * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.0 ULN (≤ 5 x ULN if liver metastases are present)\n  * Total bilirubin ≤ 1.25 x ULN\n  * Calculated or measured eGFR ≥ 40 ml\u002Fmin or serum creatinine ≤ 1.5 x ULN\n  * Prothrombin time (PT), international normalized ratio (INR) and partial thromboplastin time (PTT) \\\u003C 1.5 x ULN\n* Ability to swallow capsules\n* Use of corticosteroids is allowed up to a daily dose of 10 mg prednisone or equivalent provided that the dose has been stable for at least 2 weeks prior to the start of ZEN003694 dosing and will remain stable during ZEN003694 treatment.\n* Females or males age ≥ 18 years (at time of signing informed consent)\n* Female subjects may be enrolled if they are not of childbearing potential, permanently sterile or who are post-menopausal defined as no menses for at least 1 year without an alternative medical cause and FSH levels in the post-menopausal range. Female subjects of childbearing potential may be enrolled if they consistently and correctly use a highly effective form of contraception. Highly effective forms of contraception include: combined (estrogen and progestogen hormonal contraceptives (oral, intravaginal, transdermal) associated with inhibition of ovulation; progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence. Female subjects should not donate eggs from the time point of study drug administration until at least 7 months thereafter.\n* Males with partners of childbearing potential may be enrolled if they use a condom when having sex with a pregnant woman or with a non-pregnant female of childbearing potential from 21 days before the first dose of study drug through 4 months after the last dose of study drug, and males should not donate sperm from the time point of study drug administration until at least 4 months thereafter.\n\nContraception should be considered for a non-pregnant female partner of childbearing potential\n\n* Females of childbearing potential must have a negative serum or urine pregnancy test before the first dose of study drugs and must agree to pregnancy tests during the study.\n* Females may not be breast-feeding at the first dose of study drugs, during study participation or through 7 months after the last dose of study drugs\n\nExclusion Criteria:\n\n* Have previously received an investigational BET inhibitor\n* Have received prior systemic anti-cancer therapy or investigational therapy within 2 weeks or five half-lives, whichever is shorter, prior to the first dose of study drug\n* Radiation therapy within 2 weeks of first dose of study drug\n* Currently receiving medications known to be strong inducers or inhibitors of CYP3A4 and substrates of CYP1A2 with a narrow therapeutic window. Strong inducers and inhibitors of CYP3A4 and CYP1A2 substrates with narrow therapeutic ranges must be discontinued at least 7 days prior to the first administration of study drug.\n* Left ventricular ejection fraction less than the lower of 50% or the lower limit of institution's normal range\n* QTcF interval \\> 470 msec\n* Known impaired cardiac function or clinically significant cardiac disease such as uncontrolled supraventricular arrhythmia, ventricular arrhythmia requiring therapy, or uncontrolled congestive heart failure (New York Heart Association functional class III or IV)\n* Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug\n* Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active CNS disease, active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, or any other condition that could compromise safety or the patient's participation in the study\n* Other known active cancer requiring therapy at time of study entry\n* Historically positive (screening tests not required) for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or with active infections. HBV positivity defined by positive hepatitis B surface antigen (HBsAg). HCV positivity defined as positive HCV viral load.\n* Major surgery other than diagnostic surgery, dental surgery or stenting within 4 weeks prior to the first administration of study drug\n* History of congenital or other deficiency in platelet function, or any known inherent or acquired coagulopathy, including current anticoagulation therapy (except for low-dose warfarin for port patency)\n* Current or anticipated use within 7 days prior to the first administration of study drug, or during the study, of strong P-gp inhibitors.\n* Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed. Note: except for subjects on anticoagulant therapy who must have PT-INR within therapeutic range as deemed appropriate by the Investigator.","ALL","18 Years",{"count":19,"type":20},13,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene.\n\nZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.",[26],"Squamous Cell Lung Cancer",[28,29,30,31,32],"Metastatic","Recurrent","ZEN003694","NSD3 Amplification","22-286","RECRUITING","2026-03-09",{"date":36,"type":37},"2026-03-11","ACTUAL",{"date":39,"type":37},"2022-11-01",{"date":41,"type":20},"2027-11",{"name":43,"class":44},"Memorial Sloan Kettering Cancer Center","OTHER",7,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100627103","phase-1-an-phase-i-trial-of-a-car-t-cell-infusion-c-car031-in-participants-with-gpc3-advancedmetastatic-squamous-cell-lung-cancer-100627103","NCT07444281","An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced\u002FMetastatic Squamous Cell Lung Cancer","An Investigator-initiated Phase I Trial of an Armored and GPC3-targeted Autologous CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced\u002FMetastatic Squamous Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed unresectable Stage IIIB ,IIIC or IV squamous cell lung cancer\n* Confirmed to express GPC3, as assessed by immunohistochemistry at a central lab\n* Participants who have progressed or intolerant to no more than three lines of prior systemic therapies for advanced\u002Fmetastatic squamous cell lung cancer\n* At least one measurable target lesion\n* The left ventricular ejection fraction (LVEF) measured by echocardiography ≥50% and reported as non-impaired.\n* Sufficient pulmonary function\n* The laboratory testing results meet the study requirements\n* Female participants of childbearing potential must test negative for pregnancy in serum or urine. Non-sterilized participants (males and females) agree to take effective contraceptive measures for at least 12 months and until CAR-T below lower limit of detection (LLOD) by PCR which occurs last after C-CAR031 infusion.\n\nExclusion Criteria:\n\n* known to harbor a driver mutation for which targeted standard therapy is recommended in accordance with local treatment guidelines.\n* Known life-threatening allergies, hypersensitivity, or intolerance to the CAR-T product or its excipients, including dimethyl sulfoxide (DMSO)\n* Contraindication to lymphodepleting agents, including fludarabine and\u002For cyclophosphamide.\n* History of splenectomy or organ transplantation\n* Prior treatment with Any CAR-T therapy OR any therapy that is targeting GPC3\n* Uncontrolled or intercurrent pulmonary disease\n* Clinically meaningful ascites\n* Uncontrolled pleural effusion or pericardial effusion requiring recurrent drainage procedures\n* Cancer-related spinal cord compression, leptomeningeal disease, or brain metastases\n* Received radiation therapy, local treatment, vaccine, blood transfusion, systemic treatment within certain period of apheresis required by study protocol\n* History of or with active diseases or conditions of that's defined in study protocol","75 Years",{"count":55,"type":20},24,[57],"PHASE1","This single-arm, open-label, multicenter, Phase I study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK)\u002Fpharmacodynamics (PD), biomarker, and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced\u002Fmetastatic squamous cell lung cancer, who are not amenable to curative therapy and have progressed or are intolerant to no more than 3 lines of prior systemic treatment including immune checkpoint inhibitors (CPIs) and platinum-based doublet chemotherapy, concurrently or sequentially.",[26],[61,62,63],"squamous cell lung cancer","advanced squamous cell lung cancer","metastatic squamous cell lung cancer","2026-02-27",{"date":66,"type":37},"2026-03-03",{"date":68,"type":37},"2024-12-25",{"date":70,"type":20},"2028-01-30",{"name":72,"class":73},"Shanghai AbelZeta Ltd.","INDUSTRY",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100593706","phase-2-phase-ii-study-of-platinum-cisplatincarboplatinand-polymeric-micelles-paclitaxelpm-pac-with-ivonescimab-in-first-line-metastatic-squamous-nsclc-100593706","NCT07009925","Phase II Study of Platinum (Cisplatin\u002FCarboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.","Ivonescimab Combined With Polymeric Micelles Paclitaxel(Pm-Pac) and Platinum (Cisplatin\u002FCarboplatin) as First-line Treatment for Patients With Advanced Squamous NSCLC: A Multicenter, Open-label, Single-arm Clinical Study.","Inclusion Criteria:\n\n1. Written informed consent must be signed before implementing any trial-related procedures;\n2. Age ≥18 years old;\n3. Patients with histologically or cytologically confirmed metastatic or recurrent (stage IV) squamous NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging), inoperable or inappropriate for radical concurrent chemoradiotherapy, and without previous systemic treatment；. Patients with mixed histology (example adenosquamous) are allowed if there is squamous component in the specimen. PD-L1 immunohistochemical results is required before enrollment.\n\n5.According to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), there is at least one measurable lesion.\n\n6.Have not received any previous systemic antitumor therapy for advanced\u002Fmetastatic diseases. Participants who have previously received platinum-based adjuvant\u002Fneoadjuvant chemotherapy, or radical chemoradiotherapy for advanced disease are allowed to enroll if the interval between disease progression or recurrence and the end of the last chemotherapy treatment is at least 6 months.\n\n7.ECOG score: 0-1 8.Expected survival time \\> 3 months 9.Normal organ function, patients should meet the following laboratory indicators:\n\n1. Blood routine test should meet the following criteria (no blood transfusion, no use of blood products, granulocyte colony-stimulating factor, or other hematopoietic growth factors within 7 days before blood routine test); White blood cell count ≥3.0x10\\^9\u002FL, absolute neutrophil count (ANC) ≥1.5x10\\^9\u002FL，Platelet count ≥100×10\\^9\u002FL Hemoglobin \\>9g\u002FdL. If patients receive blood component transfusion (red blood cells, platelets, etc.) during the screening period, blood routine test should be performed again at an interval of 1 week to meet the above criteria before continuing screening.\n2. Blood biochemical examination must meet the following criteria: Total bilirubin ≤1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) ≤2.5 times ULN (ALT, AST, or ALP≤ 5×ULN for patients with liver metastases, and ALP≤10×ULN for patients with bone metastases); Serum creatinine ≤1.5 times ULN and creatinine clearance (calculated using Cockcroft-Gault formula) ≥60 ml\u002Fmin；\n3. Normal coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN;\n4. Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. Subjects with baseline TSH beyond the normal range, but total T3 (or FT3) and FT4 are within the normal range can also be enrolled;\n5. Myocardial zymogram within the normal range (if the investor judges that the simple laboratory result is not of clinical significance, the patient is allowed to be included); 10.For female patients of childbearing age, a negative urine or serum pregnancy test should be performed within 3 days before the first study drug administration (day 1 of cycle 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is requested. Female patients who are not of childbearing age are defined as those who have been postmenopausal for at least 1 year or have undergone surgical sterilization or hysterectomy; 11.If there is a risk of conception, all patients (male or female) are required to use contraception throughout the treatment period until 180 days after the last study drug administration.\n\nExclusion Criteria:\n\n1. Currently participating in interventional clinical research treatment;\n2. Has non-squamous histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the subject is ineligible; for non-small cell histology if there is any squamous element is present (example adenosquamous), the subject is eligible; the squamous element does not have to be predominant.\n3. Previously received immunotherapy, including immune checkpoint inhibitors (such as anti-PD-1 \u002FL1 antibodies, anti-CTLA-4 antibodies, anti-LAG-3 antibodies, etc.), immune checkpoint agonists (such as: Subjects of ICOS, CD40, CD137, GITR, OX40 antibody, etc.), immune cell therapy, etc., any treatment targeting the immune mechanism of tumor action;\n4. known allergic or hypersensitive reactions to any investigational drug or any excipients thereof;\n5. Have a history of severe bleeding or coagulopathy; Clinically significant bleeding symptoms, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing up or spitting up ≥1 TSP of blood or small blood clots or only coughing up blood with no sputum, allowing inclusion of blood in the sputum), nasal bleeding (excluding nosebleed and retractive rhinorrhea) within 1 month before first administration; Imaging during the screening period showed that the tumor surrounded important blood vessels or had obvious necrosis and voids, and the researchers determined that entering the study would cause bleeding risk. Central, squamous non-small cell lung cancer with cavities and a higher risk of bleeding as determined by the investigators; Received continuous antiplatelet or anticoagulant therapy within 10 days prior to initial administration;\n6. Tumor invasion of surrounding important organs and blood vessels (such as aorta, heart and pericardium, superior vena cava, trachea, esophagus, etc.) or esophagotracheal fistula or esophagopleural fistula risk;\n7. Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (subjects who do not require drainage effusion or whose frequency of drainage is less than once per month can be enrolled);\n8. Patients with symptomatic brain metastases, meningeal metastases, or spinal cord compression;\n9. There is a history or current presence of non-infectious pneumonia\u002Finterstitial lung disease requiring systemic glucocorticoid therapy;\n10. Serious comorbidities such as a history of severe lung or heart disease, any arterial thrombosis, embolism, or ischemia within 6 months prior to treatment, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack. A history of deep vein thrombosis, pulmonary embolism, or any other severe thromboembolism within the 3 months prior to enrollment (implantable intravenous port or catheter-derived thrombosis, or superficial venous thrombosis was not considered \"severe\" thromboembolism);\n11. History of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with autoimmune related hypothyroidism receiving stable dose thyroid hormone replacement therapy were eligible to participate in the study. Patients with controlled type 1 diabetes following a stable insulin regimen were eligible to participate in the study.\n12. Active systemic infections, including tuberculosis (clinical diagnosis including clinical history, physical examination and imaging findings, and TB testing based on local medical practice), hepatitis B (known to be positive for HBV surface antigen (HBsAg), HBV DNA ≥1000cps\u002Fml or the lower limit of its reference value), hepatitis C or human immunodeficiency virus (HIV antibody positive);\n13. A known mental illness or substance abuse condition that may affect compliance with the test requirements;\n14. There is a medical history, disease, treatment, or abnormal laboratory result that could interfere with the test results or prevent the subject from fully participating in the study, or the investigator believes that participation in the study is not in the subject's best interest.",{"count":83,"type":20},38,[23],"This is a prospective, single-arm, multi-center, phase Ⅱ trial to evaluate the efficacy and safety of Polymeric Micelles paclitaxel(pm-Pac), platinum (cisplatin\u002Fcarboplatin) in combination with Ivonescimab as first-line treatment in metastatic squamous NSCLC patients.",[26],[88,89,63,90,91],"Ivonescimab","Polymeric Micelles paclitaxel","Treatment Outcome","safety","NOT_YET_RECRUITING","2025-05-30",{"date":95,"type":37},"2025-06-08",{"date":97,"type":20},"2025-06",{"date":99,"type":20},"2028-05",{"name":101,"class":44},"Jiangsu Cancer Institute & Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":112,"conditions":113,"keywords":119,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100301013","phase-1-gpc3-car-t-cells-for-immunotherapy-of-cancer-with-gpc3-expression-100301013","NCT03198546","GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression","CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial","Inclusion Criteria:\n\n1. patients with advanced HCC,which express GPC3 protein.\n2. Life expectancy \\>12 weeks\n3. Child-Pugh-Turcotte score \\\u003C7\n4. Adequate heart,lung,liver,kidney function\n5. Available autologous transduced T cells with greater than or equal to 20% expression of GPC3 CAR determined by flow-cytometry and killing of GPC3-positive targets greater than or equal to 20% in cytotoxicity assay\n6. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent. -\n\nExclusion Criteria:\n\n1. Had accepted gene therapy before;\n2. Tumor size more than 25cm;\n3. Severe virus infection such as HBV,HCV,HIV,et al\n4. Known HIV positivity\n5. History of liver transplantation\n6. Active infectious disease related to bacteria, virus,fungi,et al\n7. Other severe diseases that the investigators consider not appropriate;\n8. Pregnant or lactating women\n9. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent\u002Fkg\u002Fday)\n10. Other conditions that the investigators consider not appropriate. -",{"count":110,"type":20},30,[57],"The third\u002Ffourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and\u002For soluble TGFβ (GPC3\u002FTGFβ-CART )have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test the anti-cancer function by the GPC3\u002FTGFβ-CAR-T cells in human HCC patients with GPC3 expression. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3\u002FTGFβ-CAR-T cell immunotherapy on human will firstly be tested.",[114,115,116,117,118,26],"Hepatocellular Carcinoma","Immunotherapy","CAR","GPC3 Gene Inactivation","T Cell",[120,121,122,123,124,61,125,126,127,128,129],"Hepatocellular carcinoma","immunotherapy","CAR-T cell therapy","GPC3 or TGFβ targeting","Phase I clinical study","interventional radiology","IL7-CCL19-secreting","SCFV against PD1\u002FCTLA4\u002FTigit","knockdown of PD1\u002FHPK1","DAP10","2024-06-22",{"date":132,"type":37},"2024-06-25",{"date":134,"type":37},"2017-07-01",{"date":136,"type":20},"2036-08-01",{"name":138,"class":44},"Second Affiliated Hospital of Guangzhou Medical University",2,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":74},"100481588","apollo-11-consortium-of-italian-centers-involved-in-treatment-of-patients-with-lung-cancer-treated-with-innovative-therapies-real-world-data-and-translational-reaserch-100481588","NCT05550961","APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch","Inclusion Criteria:\n\n1. Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses;\n2. Patients must be ≥18 years of age at the time of signing the informed consent;\n3. Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies).\n\nExclusion Criteria:\n\n1. Patients who are or will be taking other unapproved antineoplastic therapies concurrently are not eligible.\n2. Patients who have not received an oncological systemic innovative therapy at any setting\n3. Patients received only local treatments (e.g., only surgery, or only radiotherapy)\n4. Patients who received only standard chemotherapy are excluded.\n5. Patients who received treatment therapies before 2010 are excluded.",{"count":147,"type":20},1200,"OBSERVATIONAL","APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a \"virtual\" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo \"unity is strength\".",[151,152,153,154,26],"NSCLC","Cancer","Lung Cancer","Adenocarcinoma of Lung",[156,157,158,159],"#NSCLC","#Immunotherapy","#Targeted Therapy","#Artificial Intelligence","2023-10-17",{"date":162,"type":37},"2023-10-23",{"date":164,"type":37},"2022-10-01",{"date":166,"type":20},"2032-10-01",{"name":168,"class":44},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"]